Filter
387
Text search:
patent
Featured
Recommendations
35
New Publications
102
Language
Document type
No document type
195
Studies & Reports
71
Guidelines
66
Manuals
24
Strategic & Response Plan
12
Fact sheets
10
Training Material
4
Situation Updates
2
Infographics
2
Resource Platforms
1
Countries / Regions
India
33
Nigeria
31
Global
11
Kenya
9
South Africa
7
Uganda
6
Malawi
5
Sierra Leone
4
Liberia
4
Ethiopia
4
Ghana
4
Nepal
4
Ukraine
4
Indonesia
3
Myanmar / Burma
3
Western and Central Europe
3
Asia
3
Africa
3
Cameroon
2
Zimbabwe
2
Germany
2
Zambia
2
Tanzania
2
Rwanda
2
Bangladesh
2
Lesotho
2
East and Southern Africa
2
West and Central Africa
2
Latin America and the Carribbean
2
Eastern Europe
2
Senegal
1
Congo, Democratic Republic of
1
Philippines
1
Pakistan
1
Mozambique
1
Papua New Guinea
1
Sudan
1
Botswana
1
Venezuela
1
Tajikistan
1
Georgia
1
Authors & Publishers
Publication Years
Category
Countries
129
Clinical Guidelines
70
Women & Child Health
28
Public Health
18
Pharmacy & Technologies
18
Key Resources
6
Capacity Building
2
Annual Report MEDBOX
1
Toolboxes
HIV
52
Pharmacy
28
COVID-19
25
AMR
24
TB
20
Caregiver
16
Global Health Education
9
NTDs
9
NCDs
8
Mental Health
7
Rapid Response
4
Conflict
3
Refugee
3
Planetary Health
3
Health Financing Toolbox
3
Disability
2
Ebola
2
Natural Hazards
1
Zika
1
Specific Hazards
1
Social Ethics
1
The report provides a brief introduction to patents and licences and their effect on the market for antiretroviral (ARV) medicines. It gives an overview of the patent landscape with respect to a select number of ARV medicines in developing countries
...
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand
...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i
...
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to medicine is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pan
...
В настоящем отчете (это уже четвертое его издание) анализируются препятствия и факторы, затрудняющие доступ к препаратам для лечения лекарственно-устойчивого туб
...
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha
...
High prices, hard-to-access human insulin, few insulin producers, and weak health systems are just some of the barriers that people with diabetes face a century after insulin was discovered, WHO notes in a new report
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
The objective of the 2022 Compendium is to compile and highlight emerging innovative health technologies for low-resource settings. It presents a snapshot of technologies that are solutions to an unmet medical/health technology need or are likely to improve health outcomes and the quality of life. H
...
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s
...
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov
...
Co-trimoxazole is a fixed-dose combination of two antimicrobial drugs (sulfamethoxazole and trimethoprim) that covers a variety of bacterial, fungal and protozoan infections. Co-trimoxazole preventive therapy is a feasible, well tolerated and inexpensive intervention for people living with HIV to re
...
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0164619 October 13, 2016
